Pharmacy Talent Search Exam (PTSE)

PTSE stands for Pharmacy Talent Search Exam. PTSE was initiated in 2010 by Pharma Publications (India’s first ISO 9001:2008 certified organization in pharmacy education).

It is a scientifically designed, Skill based Assessment which employs the 4A technique:

* Attempt

* Assess

* Analyze

* Achieve

PTSE is a move to boost the talent of aspiring Pharmacists in India.

PTSE is an honor and aid towards the development of a colorful career by providing financial and academic assistance to the students.

Rather than testing rote learning, it focuses on measuring how well SKILLS and CONCEPTS underlying the university syllabus have been learnt by the student. It provides benchmark with students all over India and is Affordable and Accessible to all students.

PTSE is for the students of Pharmacy studying in D.Pharm, B.Pharma/Pharm D and M.Pharm/MS/MBA (Healthcare/Pharma)

For More Details : Click Here

Pfizer Completes Acquisition Of Icagen

Pfizer Inc. (NYSE: PFE) has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer. Under the terms of the transaction, each issued and outstanding share of Icagen common stock has been converted into the right to receive $6.00 in cash, without interest thereon, and less any applicable withholding and transfer taxes.

Icagen is now part of Pfizer's Worldwide Research and Development organization, and will be integrated into Neusentis, Pfizer's Research Unit encompassing Pain, Sensory Disorders and Regenerative Medicine.

Enbrel® (etanercept) Patent Issued

Amgen announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel® (etanercept). This patent is owned by Hoffman-La Roche Inc. ("Roche") and exclusively licensed to Amgen. Immunex Corporation (acquired by Amgen in 2002) originally licensed this patent application from Roche in 1999, and in 2004, Amgen paid Roche a one-time payment and obtained an exclusive, fully paid-up license to the application which issued today as the '182 patent. The patent describes and claims the fusion protein that is etanercept, and by statute, the '182 patent has a term of 17 years from today.

Pfizer to Acquire Excaliard Pharmaceuticals

Pfizer Inc. (NYSE: PFE) and Excaliard Pharmaceuticals, Inc. have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the end of the year.

GPAT-2012

GPAT-2012 will be organized by the M.S. University of Baroda, Vadodara-390002 through out the country on behalf of the AICTE, New Delhi. 
Candidates interested to appear for GPAT-2012 may see the following website for detailed information and syllabus: 

http://www.gpat.in
http://www.msubaroda.ac.in
 
The application of GPAT-2012 examination can be filled ONLY ONLINE from the above mentioned websites.

The important dates for GPAT-2012 Examination are as follows:

v  Website Opens (for ONLINE Registration)

§  - Saturday, 14/01/2012

v  Website Closes (for ONLINE Registration)

§  - Monday, 20/02/2012

v  Last date for receiving of copy of Bank Challan as proof of payment for examination fee and Print out of the application form

§   - Monday, 27/02/2012

v  Date of Examination 

§  - Sunday, 06/05/2012

v  Date of declaration of Result

§  - Thursday, 31/05/2012     

(Dr. K.P. Isaac)
MEMBER SECRETORY
Source- THE TIMES OF INDIA

Bayer Healthcare to acquire Pathway Medical Technologies

Bayer HealthCare announced today that its affiliate, MEDRAD, Inc. has acquired Pathway Medical Technologies, Inc., of Kirkland, Wash. Financial terms of the agreement were not disclosed. With this acquisition, Bayer HealthCare is strengthening its MEDRAD Interventional business by expanding its presence in the field of vascular intervention technologies.

Pathway Medical Technologies is a leader in mechanical atherectomy in the field of vascular intervention. The company’s products clear out blockages in the leg, also known as Peripheral Arterial Disease or PAD.

Cipla introduces new screening technology for early detection of breast cancer

Cipla, one of the leading pharmaceutical companies from India, launched a breakthrough screening technology in India today called the 'No Touch Breast Scan (NTBS);' the first-ever painless, non-invasive and radiation-free breast scanning technique for detecting breast cancer at an early stage.

As of today, 1 in every 22 women in India is expected to be diagnosed with breast cancer in their lifetime. 
The 'No-Touch Breast Scan' would be exclusively marketed by Cipla across diagnostic centres and hospitals in India. It has already been installed at BEAMS Hospital, Mumbai and Indore and Magnolia Beauty and Clinic, Pune and would be extended by Cipla on a requirement-basis to over 20 more diagnostic centres or hospitals across India.

No Touch Breast Scan (NTBS)

Merck and Serum Institute Announce Collaboration

Merck (NYSE: MRK), known outside the United States and Canada as MSD, and Serum Institute of India Limited, an Indian company, announced an agreement to work together to develop and commercialize a pneumococcal conjugate vaccine (PCV) for use in the emerging and developing world countries. It is estimated that one out of every two children immunized in the world is vaccinated by a vaccine manufactured by Serum Institute. In addition, Merck has developed more than one-third of the world's vaccines for children, adolescents and adults.

"Serum Institute is committed to improving access to and affordability of vaccines for children throughout the world," said Cyrus Poonawalla, CMD, Chairman, Serum Institute, "In working closely with Merck in the development of this collaboration it became clear that we share parallel public health goals and that our passion for getting vaccines to everyone who needs them is made even stronger by working together." 

Piramal Healthcare acquires i-pill brand from Cipla

Piramal Healthcare and Cipla signed a definitive agreement for purchase of all intellectual property rights in India related to i-pill brand of Cipla. The deal was sealed for an aggregate consideration of Rs 95 crore. i-pill brand features in the top-300 pharmaceutical products and had sales of Rs 30.92 crore as per ORG IMS for the last twelve months. The acquisition of i-pill strengthens Piramal's over the counter (OTC) portfolio which has strong consumer brands such as Lacto Calamine skin care range, Supractiv Complete, Saridon and Polycrol antacid. 

Lupin Receives Final Approval to Market Generic Ultram® ER from US FDA

Lupin Pharmaceuticals, Inc. (LPI) announced on 29^th aug, 2011 that it has received final approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride Extended-Release Tablets, 100, 200 and 300 mg strengths. Lupin will begin shipping its Tramadol ER shortly.

Tramadol HCl ER is a centrally acting synthetic analgesic in an extended release formulation. It is the generic equivalent to Ortho-McNeil’s Ultram®* ER Tablets and is indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Tramadol HCl ER tablets had annual sales of approximately $132 million for the twelve months ended June 2011 based on IMS Health sales data.

Source: Lupin Pharma

Eli Lilly India (Lilly) and Lupin Limited (Lupin) Announced Strategic Collaboration to Help Fight the Battle against Diabetes

Eli Lilly India (Lilly) and Lupin Limited (Lupin) announced on 29^th July, 2011 that they have entered into a strategic collaboration to promote and distribute Lilly’s Huminsulin range of products, including Huminsulin RTM, Huminsulin NPHTM, Huminsulin 50/50TM, Huminsulin 30/70TM and Humapen Ergo II. Lupin’s India formulations business will promote and distribute the range of products in India and Nepal, virtually doubling the number of sales representatives behind the diabetes care product. This collaboration will double the current customer base; approximately 45,000 doctors will now be called on as a result of the new partnership.

Sanofi Aventis Acquire Universal Medicare’s Nutraceutical Business

Aventis Pharma Limited (part of the Sanofi Group) announced on 24^th August, 2011 that it has entered into a definitive agreement to acquire Universal Medicare Private Limited’s business of marketing and distribution of branded nutraceutical formulations in India. Also, approximately 750 commercial employees will transition to Aventis Pharma Ltd. The transaction has been approved by the Boards of Directors of both companies. It is expected to close in the fourth quarter of 2011, subject to certain conditions precedent.

Universal Medicare, (headquartered in Mumbai, India) manufactures markets and distributes branded nutraceutical formulations in India through their sales and marketing infrastructure. 

Here is the free online test available for all the GPAT aspirants.
This test will allow you to know the level of your preparation.
Just CLICK ON "PREGPAT" under Pages(on the right sidebar), fill the brief form & start the exam.
It is a limited time exam & there is no negative marking.
You will instantly get your result after you submit your answers.
We welcome your valuable feedback.

Online Test PREGPAT